The short version: retatrutide is a triple agonist [an agonist switches a receptor on; this one switches on three] — GLP-1, GIP [glucose-dependent insulinotropic polypeptide], and glucagon receptors — and its phase 2 trial [phase 2 tests dose and effect in hundreds of people; phase 3 is the large late-stage program regulators approve on] produced a mean weight reduction of approximately 24% at 48 weeks on the highest dose, without plateauing.
That is the strongest result ever published for a weight-loss drug. It is also a 338-person, 48-week study. Phase 3 [TRIUMPH] must still prove durability, safety at scale, and cardiovascular outcomes. The molecule is not approved, and everything sold today comes from an unregulated gray market of variable quality.
- The famous number is real: approximately 24% mean weight reduction at 48 weeks on 12 mg weekly, published in the New England Journal of Medicine in 2023 — and the curve had not flattened when the trial ended.
- The context is just as real: phase 2, roughly 338 participants, 48 weeks. That is a promising mid-stage result, not an approved therapy's evidence base.
- Comparing retatrutide's phase 2 against tirzepatide's and semaglutide's phase 3 trials is indicative, not head-to-head — different trials, different durations, different populations.
- Side effects in the trial were dominated by gastrointestinal events, dose-dependent, mostly during dose escalation — the familiar incretin pattern [incretins are the gut hormones, GLP-1 and GIP among them, that these drugs imitate], at a familiar cost.
- Phase 3 [TRIUMPH] is the whole ballgame: durability, rare harms, cardiovascular outcomes. Until it reads out, "strongest data ever" and "unproven" are both accurate descriptions of the same molecule.
The number that sells vials
The 24% figure is real. It travels without its phase, its sample size or its approval status attached.
Spend ten minutes where research peptides are discussed and you will meet the 24% figure.
It appears in vendor product descriptions, group-buy threads, and social clips with the confidence of settled science. Usually it sits next to language that quietly positions retatrutide as the successor to tirzepatide, one tier up in some finished hierarchy.
What almost never travels with the number: the phase, the sample size, the duration, or the fact that no regulator on earth has reviewed this molecule for approval.
That omission is not an accident. A phase 2 result stripped of its context is a better sales asset than a phase 2 result with its context attached.
Our job here is the opposite of a sales asset, so we will give you both. The data is genuinely remarkable. The boundaries of the data are what the market has strong incentives to blur.
What a triple agonist is
Semaglutide activates one receptor, tirzepatide two, retatrutide three. The third is glucagon, and it is the genuinely new part.
Semaglutide — sold as Ozempic, Wegovy, and Rybelsus — activates one receptor: GLP-1. Tirzepatide — Mounjaro and Zepbound — activates two: GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and the glucagon receptor. That third target is the new mechanism, and it changes the character of the drug.
GLP-1 and GIP agonism work mainly on the intake side: appetite suppression, slower gastric emptying, improved glycemic signaling. Glucagon-receptor agonism is thought to add an expenditure effect: increased energy use, with hepatic effects that showed up in the trial data as well.
In plain terms, the first two mechanisms help you eat less, and the third may help you burn more. Is that combination a breakthrough, or a trade-off with costs that only appear at scale? That is exactly the kind of question phase 2 trials are too small to answer.
What phase 2 showed
338 adults, 48 weeks, 12 mg weekly, roughly 24% mean weight reduction — and the curve had not flattened when the trial ended.
The trial to know is Jastreboff and colleagues, published in the New England Journal of Medicine in 2023. Roughly 338 adults with obesity, randomised across placebo and several retatrutide doses, followed for 48 weeks.
On the highest dose — 12 mg weekly — mean weight reduction was approximately 24%. Two details matter as much as the headline figure.
First, the dose-response was clean: more drug, more loss, in an orderly pattern across arms. Second, and more striking, the weight-loss curves had not plateaued at 48 weeks. Participants on the higher doses were still losing when the trial ended.
For comparison, semaglutide's and tirzepatide's pivotal trials ran 68 and 72 weeks and captured something closer to a full arc.
Retatrutide's 24% is, in a sense, an unfinished number. That cuts both ways. The final figure could be higher. It could also come with problems a 48-week window never had time to reveal.
Three trials, side by side
Retatrutide’s mid-stage number is larger than the approved drugs’ late-stage numbers. Different trials and different populations, so it is a direction, not a ranking.
Here is the comparison everyone makes, in table form. Read the warning under it before you repeat it.
| compound | trial | phase | duration | top dose | mean weight reduction | status |
|---|---|---|---|---|---|---|
| Retatrutide | Jastreboff et al., NEJM 2023 | 2 | 48 wk | 12 mg weekly | ~24% [not plateaued] | Not approved · phase 3 [TRIUMPH] ongoing |
| Tirzepatide | SURMOUNT-1, NEJM 2022 | 3 | 72 wk | 15 mg weekly | ~20.9% | Approved [Mounjaro · Zepbound] |
| Semaglutide | STEP 1, NEJM 2021 | 3 | 68 wk | 2.4 mg weekly | ~14.9% | Approved [Ozempic · Wegovy · Rybelsus] |
The warning label: these are three different trials with different durations, different populations, different eras of obesity-trial design, and different phases of evidence. Lining their numbers up in one table — as we just did, as everyone does — is indicative, not head-to-head.
No published trial has put retatrutide in the same room as tirzepatide or semaglutide. The honest reading is that retatrutide's mid-stage data points toward something larger than the approved drugs achieved in late-stage trials. The dishonest reading, which you will encounter daily, is that a ranking has been established. It has not.
Side effects, unairbrushed
Nausea, vomiting, diarrhoea and constipation, dose-dependent and worst during escalation. The familiar incretin bill, and a dysesthesia signal that phase 2 did not show.
The tolerability story in the phase 2 trial was the familiar incretin story, scaled to a stronger drug. Adverse events were dominated by gastrointestinal effects — nausea, vomiting, diarrhea, constipation. They were dose-dependent and concentrated during dose escalation, the same pattern semaglutide and tirzepatide established before it.
The trial used gradual dose escalation specifically to manage this, and slower escalation appeared to help.
Two things follow from that. First, retatrutide is not a free lunch. The strongest efficacy data ever published came with a real GI burden, experienced at pharmaceutical-grade purity under medical supervision.
Second, the glucagon-receptor mechanism adds physiology the older drugs do not touch. Heart-rate observations in the trial drew attention, and effects involving new mechanisms are precisely what small trials are underpowered to characterize.
That is not a reason for alarm. It is the reason phase 3 exists. For a grounded look at what incretin-class side effects look like in practice, our side-effects fundamentals page covers the class.
What phase 3 must prove
Durability, rare harms and cardiovascular outcomes. A 338-person trial cannot reach any of the three.
Lilly's phase 3 program is called TRIUMPH, and it is running now, registered on clinicaltrials.gov. Until it reads out and regulators rule, three questions stay open. They are not small ones.
Durability. The phase 2 curves were still falling at 48 weeks. Where do they land at 68 or 80 weeks, and what does maintenance look like? Every drug in this class shows regain after discontinuation. How retatrutide behaves over a full arc is simply unknown.
Safety at scale. A 338-person trial can find common side effects. It cannot find the one-in-two-thousand harm. Phase 3 programs enroll thousands of participants across many sites because that is the only way rare events surface.
Tirzepatide and semaglutide have cleared this bar and accumulated years of post-approval exposure. Retatrutide has not started it in earnest.
Cardiovascular outcomes. The approved incretins built their standing partly on cardiovascular-outcome data. Retatrutide's glucagon component makes this question sharper, not softer. A mechanism that raises energy expenditure needs its cardiovascular story told in a large trial, not inferred from a mid-stage one.
The gray market isn't waiting
The molecule is approved nowhere and sold widely. No regulator has verified the contents of any vial being sold.
Here is the collision at the center of this article. The evidence base says: promising, mid-stage, unproven. The market says: in stock. Retatrutide is one of the most widely sold molecules in the research-compound economy right now. It is vialed, labeled, and shipped by vendors who range from genuinely rigorous to functionally anonymous.
None of it is pharmaceutical product. All of it exists outside the approval framework, which means no regulator has verified what is in any given vial.
The quality spread in that market is the real story, and we have covered it at length. Purity, identity, fill accuracy, and endotoxin load vary lot to lot and vendor to vendor. The paperwork that is supposed to document them is frequently missing, recycled, or decorative.
If you are evaluating that market at all, two of our reports are the necessary background. The first is how to read a certificate of analysis, covering the five measures that matter and how to catch a fake. The second is where peptide powder actually comes from, which traces the supply chain those certificates are supposed to describe.
The regulatory pressure building around that supply chain is its own story, covered in our 2026 policy report.
What you will not find here is a dosing protocol. This is an evidence piece. The evidence for this molecule comes from a trial whose escalation schedule was designed for a drug of known purity under medical supervision. The gray market does not reproduce those conditions.
General principles of how research dosing is discussed live in our dosing fundamentals, and our compound index holds the profile pages.
reader skillsLooking at any of these compounds regardless? Read the certificate before the claim.The five measures a real COA carries, what most certificates skip, and how to verify one with the lab — in five minutes.→The community file
Across our August 2026 community sweep, one GLP report recurs above everything else: the food noise stops. It is also the report least able to prove anything about a gray-market vial.
We swept the GLP self-sourcing communities — the tirzepatide and retatrutide subreddits, the long threads, the YouTube comment records — through the framework in our community evidence report. The positive record is not marginal, and it clusters tightly:
- Quieter food preoccupation is the dominant report, by recurrence and by specificity. "Food noise is almost completely gone" [Reddit, May 2024] — framed by the user as regained mental space, not a scale result. On retatrutide: "Food noise is ancient history, and energy levels are good" [Reddit, Dec 2025] — from a report that also documents a calorie deficit, protein targets and frequent strength training, which is the confound stated in the same breath.
- Non-scale reports are common and diffuse — sleep, energy, less interest in alcohol, less joint pain, fewer migraines, one user reporting tirzepatide "worked better than any medication I've been prescribed for my fibromyalgia" [Reddit, May 2026]. Read as the framework reads them: hypothesis-generating, uncontrolled, and heavily mediated by weight loss and behavior change themselves.
- The record is mixed inside single reports — one commenter "loves how my brain feels" while reporting cold sensitivity and hair loss in the same breath [YouTube, Jun 2026]. Honest reading cuts both ways.
Two hard limits keep this file in its place. First, food-noise suppression is exactly the mechanism the approved trials already established for this class. The community is corroborating pharmacology on subjective ground, not extending it.
Second, and decisive for this market: the post-use experience and the vial label are not independent confirmation of each other.
A prescribed pen validates nothing about a research vial. Retatrutide is approved nowhere, and Lilly states it is legally available only through its trials. FDA's position on unapproved GLP products is that they are reviewed for nothing — not safety, not effectiveness, not quality.
The community's own testing layer keeps demonstrating why that matters. That is the certificate question again.
Holding both facts
Strongest obesity data yet published, and still unproven, are the same sentence. That is what phase 2 looks like from the inside.
The strongest weight-loss data ever published. Still unproven. The market treats these as contradictory, and picks whichever half sells. They are not contradictory. They are the normal state of a drug between phase 2 and phase 3.
What that state is not is a near-certainty. Published estimates of clinical development success put the odds of reaching approval from phase 2 well under half, across every therapeutic area.
A strong mid-stage result improves those odds. It does not settle them. The 24% number deserves the attention it gets. The 338-person, 48-week, unapproved context deserves to travel with it, every time. When you see the number without the context, you have learned something about the source.
FAQ
Is retatrutide FDA-approved?
No. Retatrutide has completed a phase 2 trial and is in phase 3 development under Lilly's TRIUMPH program, registered on ClinicalTrials.gov. It is not approved anywhere, for anything, by any regulator.
That has a practical consequence people read past: every vial sold today is sold outside the drug approval framework, which means no regulator has verified what is in it.
Retatrutide is nonetheless one of the most widely sold molecules in the research-compound economy right now. It is vialed, labeled and shipped by vendors who range from genuinely rigorous to functionally anonymous. None of it is pharmaceutical product.
Here is the caveat that matters for anyone reading the phase 2 headline as a foregone conclusion. Published estimates of clinical development success put the odds of reaching approval from phase 2 well under half, across every therapeutic area. A strong mid-stage result improves those odds. It does not settle them.
What did the phase 2 trial actually show?
The trial to know is Jastreboff and colleagues, published in the New England Journal of Medicine in 2023. Roughly 338 adults with obesity were randomised across placebo and several retatrutide doses and followed for 48 weeks.
On the highest dose, 12 mg weekly, mean weight reduction was approximately 24%. Two details matter as much as the headline figure. The dose-response was clean — more drug, more loss, in an orderly pattern across arms.
And the weight-loss curves had not plateaued at 48 weeks: participants on the higher doses were still losing when the trial ended. That makes 24% an unfinished number, which cuts both ways.
Semaglutide's and tirzepatide's pivotal trials ran 68 and 72 weeks and captured something closer to a full arc. The final retatrutide figure could be higher. It could also carry problems a 48-week window never had time to reveal.
Is retatrutide stronger than tirzepatide or semaglutide?
Its phase 2 number is larger than their phase 3 numbers. That is approximately 24% at 48 weeks, against tirzepatide's roughly 20.9% in SURMOUNT-1 over 72 weeks and semaglutide's roughly 14.9% in STEP 1 over 68 weeks.
Lining those up in one table, as we do and as everyone does, is indicative, not head-to-head. They are three different trials with different durations, different populations, different eras of obesity-trial design, and different phases of evidence.
No published trial has put retatrutide in the same room as tirzepatide or semaglutide. The honest reading is that retatrutide's mid-stage data points toward something larger than the approved drugs achieved in late-stage trials.
The dishonest reading, which you will encounter daily, is that a ranking has been established. It has not. Two of these molecules are approved and dosed under supervision. The third is approved nowhere.
What is a triple agonist?
A molecule that switches on three receptors at once. Here they are GLP-1, GIP, and glucagon. Semaglutide — sold as Ozempic, Wegovy and Rybelsus — activates one receptor, GLP-1.
Tirzepatide — Mounjaro and Zepbound — activates two, GLP-1 and GIP. Retatrutide adds the glucagon receptor, and that third target is the genuinely new part. GLP-1 and GIP agonism work mainly on the intake side: appetite suppression, slower gastric emptying, improved glycemic signaling.
Glucagon-receptor agonism is thought to add an expenditure effect — increased energy use, with hepatic effects that showed up in the trial data as well.
In plain terms, the first two mechanisms help you eat less and the third may help you burn more. Whether that combination is a breakthrough or a trade-off with costs that only appear at scale is exactly what a 338-person trial is too small to answer.
When will phase 3 results arrive?
TRIUMPH is a multi-trial program and its readouts arrive in stages rather than on one date, so there is no single answer to give. What the program still has to prove is the more useful question, and it has three parts.
Durability: the phase 2 curves were still falling at 48 weeks, and every drug in this class shows regain after discontinuation. Safety at scale: a 338-person trial can find common side effects but not the one-in-two-thousand harm, which is why phase 3 programs enroll thousands of participants across many sites.
Cardiovascular outcomes: the approved incretins built their standing partly on cardiovascular-outcome data, and retatrutide's glucagon component makes that question sharper, not softer. Until TRIUMPH reads out and regulators rule, all three stay open. That is why the strongest weight-loss data ever published and an unproven molecule are the same sentence.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526 — PMID 37366315.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity [SURMOUNT-1]. N Engl J Med. 2022;387:205-216 — PMID 35658024.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity [STEP 1]. N Engl J Med. 2021;384:989-1002 — PMID 33567185.
- Lilly's TRIUMPH phase 3 program for retatrutide — trial registrations searchable at clinicaltrials.gov — no TRIUMPH trial has posted results or a publication
- Inside Your Peptides, How to Read a COA — the five measures that matter
- Inside Your Peptides, Where Peptide Powder Comes From — the supply-chain report
disclosure: inside your peptides is published by the owners of the next lab, the only vendor we are paid by elsewhere on this site — this article carries none. grades and rankings follow the published criteria in our editorial policy — never referral terms. research + education only · not medical advice.